NCT02118064View on ClinicalTrials.gov

Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

December 31, 2002

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

G17DT-Irinotecan

500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes.

Sponsors
All Listed Sponsors
lead

Cancer Advances Inc.

INDUSTRY

NCT02118064 - Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma | Biotech Hunter | Biotech Hunter